A new obesity drug, Wegovy, slashed the risk of serious heart problems by 20 percent in a large trial, the drug’s maker said on Tuesday, a finding that could put pressure on insurers to cover the in-demand treatment.The trial — the first to demonstrate that one of the new class of obesity drugs could also…
